The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921488" target="_blank" >RIV/00023752:_____/25:43921488 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10493317 RIV/00216208:11120/25:43928061 RIV/60461373:22330/25:43932000 RIV/60461373:22340/25:43932000 RIV/00064165:_____/25:10493317
Result on the web
<a href="https://doi.org/10.1016/j.pnpbp.2025.111285" target="_blank" >https://doi.org/10.1016/j.pnpbp.2025.111285</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.pnpbp.2025.111285" target="_blank" >10.1016/j.pnpbp.2025.111285</a>
Alternative languages
Result language
angličtina
Original language name
The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model
Original language description
Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
<a href="/en/project/VK01010212" target="_blank" >VK01010212: New psychoactive substances: forensic-toxicology research center</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Progress in Neuro-Psychopharmacology & Biological Psychiatry
ISSN
0278-5846
e-ISSN
1878-4216
Volume of the periodical
137
Issue of the periodical within the volume
111285
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
1-10
UT code for WoS article
001426467800001
EID of the result in the Scopus database
2-s2.0-85217152882